2024-2025 COVID-19 Vaccine and Major Adverse Cardiovascular Events Among US Veterans
Listen to this summary
The study aimed to determine whether the 2024-2025 COVID-19 vaccine reduces the risk of COVID-19-associated major adverse cardiovascular events (MACEs) among US veterans. The findings indicated that the vaccine was associated with a 37.7% reduction in COVID-19-associated MACEs, particularly in individuals over 75 years old and those with comorbidities, while also showing a more substantial reduction in all-cause MACEs. This suggests that the vaccine may provide broader protective benefits beyond COVID-19-related complications.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from JAMA internal medicine
View all →Jun 22, 2026 · JAMA internal medicine
Apolipoprotein L1 Gene Genotype and Kidney Outcomes After Living Kidney Donation
Jun 22, 2026 · JAMA internal medicine
Multilevel Stewardship Intervention for Use of Anticoagulation-Antiplatelet Therapy
Jun 15, 2026 · JAMA internal medicine
Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults
Jun 8, 2026 · JAMA internal medicine
Structured Telehealth Community Health Worker-Clinician Feedback and Diabetes Outcomes: A Randomized Clinical Trial
Jun 8, 2026 · JAMA internal medicine
Rehospitalization and the Association of Postoperative Delirium With Cognitive Decline in Older Adults
Jun 1, 2026 · JAMA internal medicine
Evaluating the Consequences of a Hypertension Management Incentive
More in Internal Medicine
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
